MyBiotics Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MyBiotics Pharma Ltd.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
- Digital Health
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.